Retatrutide, a novel dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising data in preliminary clinical assessments . Ongoing research https://yesbookmarks.com/story21457739/retatrutide-emerging-research-and-potential-clinical-roles